scholarly journals Polymorphism of ACE, AGT, AGTR1 genes as genetic predictors of hypertension

2021 ◽  
Vol 26 ◽  
pp. 4143
Author(s):  
A. Yu. Elkina ◽  
N. S. Akimova ◽  
Yu. G. Shvarts

The genetic architecture of blood pressure (BP) includes more than 30 genes, the polymorphic variants of which cause phenotypic heterogeneity of BP. Given that a human genetic information is largely stable from birth, it can act as an early predictor of hypertension (HTN). Identification of polymorphic variants of genes associated with a high HTN risk may be one of the promising areas of early diagnosis and prevention of this disease. In addition, the availability of this data will make it possible to clarify the prognosis of patients already with HTN, as well as to personalize the treatment approach. The review analyzes the papers devoted to the molecular genetic basis of hypertension and identifies the possible role of gene polymorphism of the renin-angiotensin-aldosterone system in hypertension development. A large number of studies have revealed an association between HTN and polymorphic variants of the ACE, AGT, AGTR1 genes. In addition, polymorphism of these genes is involved in the development of atherosclerosis and related diseases, kidney and central nervous system disorders, and justifies the effectiveness of angiotensin-converting enzyme inhibitors in the treatment of HTN.

Kardiologiia ◽  
2020 ◽  
Vol 60 (4) ◽  
pp. 4-9 ◽  
Author(s):  
Yu. V. Mareev ◽  
V. Yu. Mareev

The review addressed the relationship of coronavirus disease 2019 (COVID-19) with functioning of the renin-angiotensin-aldosterone axis and the causes for unfavorable prognosis depending on patients’ age and comorbidities. The authors discussed in detail potential effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists on the risk of infection and the course of COVID-2019 as well as the effect of SARS-COV2 virus on the cardiovascular system.


2019 ◽  
Vol 5 (2) ◽  
pp. e16-e16
Author(s):  
Masoumeh Asgharpour ◽  
Mohammad Ebrahimi Kalan ◽  
Seyed Hadi Mirhashemi ◽  
Amirhesam Alirezaei

Angiotensin-converting enzyme inhibitors (ACEIs) are among the most widely prescribed antihypertensive medications. They are indicated in the management of multiple chronic conditions including hypertension, diabetes mellitus and heart failure. ACEIs prevent angiotensin II (Ang II) production and bradykinin catabolism leading to vasodilation and reduction of arterial blood pressure. Recently, the role of the reninangiotensin system (RAS) inhibitors has become the subject of scrutiny in the treatment of cancer metastasis. The administration of ACEIs, however, has been described to be accompanying with carcinogenic effects.


2011 ◽  
Vol 148 (3) ◽  
pp. 377-379 ◽  
Author(s):  
Aleksandr Korniyenko ◽  
Carlos L. Alviar ◽  
Juan P. Cordova ◽  
Franz H. Messerli

Sign in / Sign up

Export Citation Format

Share Document